Cetera Investment Advisers Buys 173 Shares of argenex SE $ARGX

Cetera Investment Advisers boosted its position in shares of argenex SE (NASDAQ:ARGX) by 3.2% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,664 shares of the company’s stock after buying an additional 173 shares during the quarter. Cetera Investment Advisers’ holdings in argenex were worth $3,122,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the business. Lord Abbett & CO. LLC grew its stake in argenex by 33.2% in the first quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company’s stock worth $162,585,000 after purchasing an additional 68,498 shares in the last quarter. Millennium Management LLC raised its holdings in shares of argenex by 316.9% in the first quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock worth $158,977,000 after buying an additional 204,180 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of argenex by 6.1% in the second quarter. Jennison Associates LLC now owns 264,647 shares of the company’s stock valued at $145,879,000 after purchasing an additional 15,186 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in argenex by 4.8% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 184,987 shares of the company’s stock valued at $100,350,000 after acquiring an additional 8,537 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in argenex by 14.8% in the first quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock valued at $99,886,000 after purchasing an additional 21,805 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenex Trading Down 0.0%

Shares of NASDAQ ARGX opened at $917.63 on Friday. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.13. The stock has a market cap of $56.50 billion, a P/E ratio of 39.40, a P/E/G ratio of 0.92 and a beta of 0.45. The stock has a 50 day moving average of $828.68 and a two-hundred day moving average of $690.94.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating analysts’ consensus estimates of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.07 billion. As a group, research analysts predict that argenex SE will post 3.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ARGX has been the topic of several analyst reports. Bank of America raised their price target on shares of argenex from $880.00 to $887.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Wedbush raised their target price on shares of argenex from $880.00 to $1,000.00 and gave the stock an “outperform” rating in a research note on Friday, November 14th. Wells Fargo & Company lifted their target price on shares of argenex from $741.00 to $756.00 and gave the stock an “overweight” rating in a research note on Thursday, July 31st. HC Wainwright boosted their price objective on shares of argenex from $774.00 to $915.00 and gave the company a “buy” rating in a report on Friday, October 31st. Finally, Wolfe Research reaffirmed a “peer perform” rating on shares of argenex in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, argenex presently has a consensus rating of “Moderate Buy” and an average target price of $903.78.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.